Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
Xue BaiJiani HuAllison Betof WarnerHenry T QuachChristopher G CannMichael Z ZhangLu SiBixia TangChuanliang CuiXiaoling YangXiaoting WeiLalit PallanCatriona HarveyMichael P ManosOlivia OuyangMichelle S KimGyulnara KasumovaJustine V CohenDonald P LawrenceChristine FreedmanRiley M FaddenKrista M RubinTatyana SharovaDennie T FrederickKeith T FlahertyOsama E RahmaGeorgina V LongAlexander M MenziesJun GuoAlexander N ShoushtariDouglas B JohnsonRyan J SullivanGenevieve Marie BolandPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Early high-dose GCC use was associated with poorer PFS and OS after irAE onset. Judicious use of GCC early during anti-PD-1 monotherapy should be considered. Further prospective randomized control clinical trials designed to explore alternative irAE management options are warranted.